Aytu BioPharma Analyst Ratings
Aytu BioPharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 204.88% | Maxim Group | → $5 | Initiates Coverage On | → Buy |
| 05/31/2023 | 1119.51% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 07/21/2022 | 265.85% | HC Wainwright & Co. | $11 → $6 | Maintains | Buy |
| 05/17/2022 | 204.88% | Cantor Fitzgerald | $11 → $5 | Maintains | Overweight |
| 04/28/2022 | 570.73% | HC Wainwright & Co. | $24 → $11 | Maintains | Buy |
| 03/30/2021 | 570.73% | Cantor Fitzgerald | → $11 | Initiates Coverage On | → Overweight |
| 05/29/2020 | 82.93% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
| 10/22/2018 | 509.76% | Northland Capital Markets | → $10 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/09/2023 | 204.88% | Maxim 集團 | → 5 美元 | 啓動覆蓋開啓 | → 購買 |
| 05/31/2023 | 1119.51% | HC Wainwright & Co. | → 20 美元 | 重申 | 購買 → 購買 |
| 2022 年 7 月 21 日 | 265.85% | HC Wainwright & Co. | 11 美元 → 6 美元 | 維護 | 購買 |
| 05/17/2022 | 204.88% | 坎託·菲茨傑拉德 | 11 美元 → 5 美元 | 維護 | 超重 |
| 04/28/2022 | 570.73% | HC Wainwright & Co. | 24 美元 → 11 美元 | 維護 | 購買 |
| 03/30/2021 | 570.73% | 坎託·菲茨傑拉德 | → 11 美元 | 啓動覆蓋開啓 | → 超重 |
| 2020 年 5 月 29 日 | 82.93% | HC Wainwright & Co. | → 3 美元 | 啓動覆蓋開啓 | → 購買 |
| 10/22/2018 | 509.76% | 北國資本市場 | → 10 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
What is the target price for Aytu BioPharma (AYTU)?
Aytu BioPharma（AYTU）的目標價格是多少？
The latest price target for Aytu BioPharma (NASDAQ: AYTU) was reported by Maxim Group on August 9, 2023. The analyst firm set a price target for $5.00 expecting AYTU to rise to within 12 months (a possible 204.88% upside). 2 analyst firms have reported ratings in the last year.
Maxim集團於2023年8月9日公佈了Aytu BioPharma（納斯達克股票代碼：AYTU）的最新目標股價。這家分析公司將目標股價定爲5.00美元，預計AYTU將在12個月內升至12個月內（可能上漲204.88％）。去年有2家分析公司公佈了評級。
What is the most recent analyst rating for Aytu BioPharma (AYTU)?
分析師對Aytu BioPharma（AYTU）的最新評級是多少？
The latest analyst rating for Aytu BioPharma (NASDAQ: AYTU) was provided by Maxim Group, and Aytu BioPharma initiated their buy rating.
Aytu BioPharma（納斯達克股票代碼：AYTU）的最新分析師評級由Maxim集團提供，Aytu BioPharma啓動了買入評級。
When is the next analyst rating going to be posted or updated for Aytu BioPharma (AYTU)?
Aytu BioPharma（AYTU）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aytu BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aytu BioPharma was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Aytu BioPharma的高管和客戶交談以及聽取業績電話會議）後得出股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Aytu BioPharma的最後一次評級是在2023年8月9日提交的，因此您應該預計下一個評級將在2024年8月9日左右公佈。
Is the Analyst Rating Aytu BioPharma (AYTU) correct?
分析師對Aytu BioPharma（AYTU）的評級正確嗎？
While ratings are subjective and will change, the latest Aytu BioPharma (AYTU) rating was a initiated with a price target of $0.00 to $5.00. The current price Aytu BioPharma (AYTU) is trading at is $1.64, which is within the analyst's predicted range.
雖然評級是主觀的，會發生變化，但最新的Aytu BioPharma（AYTU）評級是最初的，目標股價爲0.00美元至5.00美元。Aytu BioPharma（AYTU）目前的交易價格爲1.64美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。